Bladder cancer breakthrough? new drug combo aims to stop tumors returning

NCT ID NCT06488222

Recruiting now Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether giving two chemotherapy drugs (gemcitabine and docetaxel) directly into the bladder can prevent low-grade bladder cancer from coming back. About 34 adults with intermediate-risk disease will receive the treatment. The main goal is to see how long people stay cancer-free after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine and docetaxel (given directly into the bladder)
What this could lead to: If successful, this could offer a new treatment option to lower the chance of bladder cancer coming back in people with low-grade intermediate-risk disease.
What could go wrong: This is a small early-phase trial with only 34 participants, so results may not apply to everyone. The drugs may not reduce recurrence as hoped, and side effects from bladder instillation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder papillary urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

University of Florida
RECRUITING

Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.